Loading clinical trials...
Loading clinical trials...
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Conditions
Interventions
Vibegron
Placebo
Locations
140
United States
Urology Centers of Alabama
Homewood, Alabama, United States
Private Practice
Huntsville, Alabama, United States
Coastal Clinical Research, Inc.
Mobile, Alabama, United States
Gen1 Research- Arizona Urology Specialists
Glendale, Arizona, United States
Urological Associates Of Southern Arizona
Tucson, Arizona, United States
California Research Medical Group, Inc.
Fullerton, California, United States
Start Date
March 26, 2019
Primary Completion Date
June 15, 2023
Completion Date
June 15, 2023
Last Updated
August 7, 2024
NCT06789406
NCT05362292
NCT07193407
NCT07195656
NCT05799313
NCT04873037
Lead Sponsor
Urovant Sciences GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions